Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period.
Negredo
Eugènia
E
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain.
Bonjoch
Anna
A
Paredes
Roger
R
Puig
Jordi
J
Clotet
Bonaventura
B
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D063065:Organophosphonates / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use; D000068698:Tenofovir; D013997:Time Factors; D019562:Viral Load
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D063065:Organophosphonates; D010446:Peptide Fragments; D000077560:Enfuvirtide; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine